Galectin Therapeutics Inc. (GALT) Financials
GALT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 15.8 million | 146.0 million |
| Dec. 31, 2025 | 19.5 million | 145.7 million |
| Sept. 30, 2025 | 12.9 million | 138.2 million |
| June 30, 2025 | 15.6 million | 132.8 million |
GALT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -3.9 million | 686000 |
| Dec. 31, 2025 | -6.0 million | 195000 |
| Sept. 30, 2025 | -3.5 million | 496000 |
| June 30, 2025 | -6.6 million | 500000 |
GALT Net Income
No data available :(
GALT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 14.1 million | 135.7 million | 6000 |
| Dec. 31, 2025 | 17.7 million | 133.7 million | 22000 |
| Sept. 30, 2025 | 11.5 million | - | 37000 |
| June 30, 2025 | 13.8 million | 120.5 million | 52000 |
GALT Shares Outstanding
GALT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 2.2 million | 1.8 million | - |
| Dec. 31, 2025 | - | 1.9 million | 1.4 million | - |
| Sept. 30, 2025 | - | 2.6 million | 1.6 million | - |
| June 30, 2025 | - | 3.3 million | 1.4 million | - |
GALT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 12000 |
| Dec. 31, 2025 | - | -12000 |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | 2000 |
GALT
Price: $3.47
52 week price:
Earnings Per Share: -0.41 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 205300
Ebitda: -4.4 millionMarket Capitalization: 304.9 million